gip y glp 1 LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept: Cell Metabolism PDB-101: Molecule of the Month:

[1] The prescribing clinician or diabetes specialist nurse should be consulted to confirm the appropriate timing and dosing for individual patients, particularly those with complex medical histories or those who experienced surgical complications

Tng cng bo v chc nng gan, gip thi c, tng cng min dch cho c th

When peptides clump together, they lose their bioactivity and can become immunogenic in animal models

Environmental Microbiology, 11 (7), 18971908

[Source: Fierce Pharma ] January 2025 The FDA fast-tracked tirzepatide for cardiovascular risk reduction in obesity patients, following landmark trial results showing significant benefit beyond weight loss